Dr. Palmer extra bio info: for all liver diseas
Post# of 148101
for all liver diseases including MASH and PSC, all aspects of liver disease drug development from pre-IND to NDA and launch, hepatic impairment studies, regulatory interactions including IND, NDA, and responding to regulatory feedback from the Agencies, liver adverse event signal evaluation during clinical trials, (drug-induced liver injury, formation of and chairing scientific and medical advisory boards, data-safety monitoring committees and Hepatology safety adjudication committees.
https://rectifypharma.com/